Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.
Stock data | 2024 | Change |
---|---|---|
Price | $4.16 | N/A |
Market Cap | $7.58M | N/A |
Shares Outstanding | 1.82M | N/A |
Employees | 102.00 | N/A |